

**Welcome to the Integrated Research Application System****IRAS Project Filter**

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

**Please enter a short title for this project** (maximum 70 characters)

HORIZONS: Understanding the impact of cancer diagnosis and treatment

**1. Is your project research?**

☒ Yes ☐ No

**2. Select one category from the list below:**

- ☐ Clinical trial of an investigational medicinal product
- ☐ Clinical investigation or other study of a medical device
- ☐ Combined trial of an investigational medicinal product and an investigational medical device
- ☐ Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
- ☐ Basic science study involving procedures with human participants
- ☒ Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology
- ☐ Study involving qualitative methods only
- ☐ Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)
- ☐ Study limited to working with data (specific project only)
- ☐ Research tissue bank
- ☐ Research database

**If your work does not fit any of these categories, select the option below:**

☐ Other study

**2a. Please answer the following question(s):**

- a) Does the study involve the use of any ionising radiation? ☐ Yes ☒ No
- b) Will you be taking new human tissue samples (or other human biological samples)? ☐ Yes ☒ No
- c) Will you be using existing human tissue samples (or other human biological samples)? ☐ Yes ☒ No

**3. In which countries of the UK will the research sites be located?** *(Tick all that apply)*

- ☒ England
- ☒ Scotland

- ☐ Wales  
☐ Northern Ireland

**3a. In which country of the UK will the lead NHS R&D office be located:**

- ☒ England  
☐ Scotland  
☐ Wales  
☐ Northern Ireland  
☐ This study does not involve the NHS

**4. Which applications do you require?**

*IMPORTANT: If your project is taking place in the NHS and is led from England select 'IRAS Form'. If your project is led from Northern Ireland, Scotland or Wales select 'NHS/HSC Research and Development Offices' and/or relevant Research Ethics Committee applications, as appropriate.*

- ☒ IRAS Form  
☐ Confidentiality Advisory Group (CAG)  
☐ National Offender Management Service (NOMS) (Prisons & Probation)

*For NHS/HSC R&D Offices in Northern Ireland, Scotland and Wales the CI must create NHS/HSC Site Specific Information forms, for each site, in addition to the study wide forms, and transfer them to the PIs or local collaborators.*

*For participating NHS organisations in England different arrangements apply for the provision of site specific information. Refer to IRAS Help for more information.*

**Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is your study exempt from REC review?**

- ☐ Yes ☒ No

**5. Will any research sites in this study be NHS organisations?**

- ☒ Yes ☐ No

**5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or a Diagnostic Evidence Co-operative in all study sites?**

Please see information button for further details.

- ☐ Yes ☒ No

*Please see information button for further details.*

**5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?**

Please see information button for further details.

- ☒ Yes ☐ No

*The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".*

*If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.*

**6. Do you plan to include any participants who are children?**

☐ Yes ☒ No

**7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?**

☐ Yes ☒ No

*Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.*

**8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?**

☐ Yes ☒ No

**9. Is the study or any part of it being undertaken as an educational project?**

☐ Yes ☒ No

**10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?**

☐ Yes ☒ No

**11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?**

☐ Yes ☒ No

**NOTICE OF SUBSTANTIAL AMENDMENT**

*Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of investigational medicinal products (CTIMPs).  
The form should be completed by the Chief Investigator using language comprehensible to a lay person.*

**Details of Chief Investigator:**

	Title	Forename/Initials	Surname
	Professor	Claire	Foster
Work Address	Faculty of Health Sciences, Building 67 Highfield Campus, University of Southampton University Road, Southampton		
PostCode	SO17 1BJ		
Email	C.L.Foster@soton.ac.uk		
Telephone	02380 594006		
Fax			

**For guidance on this section of the form refer to the guidance**

<b>Full title of study:</b>	HORIZONS: a cohort study to explore recovery of health and well-being in adults diagnosed with cancer
<b>Lead sponsor:</b>	University Hospital Southampton NHS Foundation Trust
<b>Name of REC:</b>	North West - Lancaster Research Ethics Committee
<b>REC reference number:</b>	16/NW/0425

**Additional reference number(s):**

Ref.Number	Description	Reference Number

<b>Name of lead R&amp;D office:</b>	University Hospital Southampton NHS Foundation Trust
<b>Date study commenced:</b>	29/07/2016
<b>Protocol reference (if applicable), current version and date:</b>	2.0 21/12/2016
<b>Amendment number and date:</b>	4 27/02/2017

**Type of amendment**

(a) Amendment to information previously given in IRAS

☒ Yes    ☐ No

If yes, please refer to relevant sections of IRAS in the "summary of changes" below.

Part C. Overview of research sites  
 Barts Health NHS Trust  
 St George's University Hospitals NHS Foundation Trust  
 NHS Lanarkshire  
 NHS Highlands

*(b) Amendment to the protocol*

☐ Yes ☒ No

*If yes, please submit either the revised protocol with a new version number and date, highlighting changes in bold, or a document listing the changes and giving both the previous and revised text.*

*(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting documentation for the study*

☒ Yes ☐ No

*If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold.*

HORIZONS 202342 baseline Q v1.0 BREAST [tracked] 07/07/2016  
 HORIZONS 202342 baseline Q v2.0 BREAST [clean] 27/02/2017  
 HORIZONS 202342 baseline Q v1.0 CERVICAL [tracked from gynae v1.0] 07/07/2016  
 HORIZONS 202342 baseline Q v2.0 CERVICAL [clean] 27/02/2017  
 HORIZONS 202342 baseline Q v1.0 ENDOMETRIAL [tracked from gynae v1.0] 07/07/2016  
 HORIZONS 202342 baseline Q v2.0 ENDOMETRIAL [clean] 27/02/2017  
 HORIZONS 202342 baseline Q v1.0 OVARIAN [tracked from gynae v1.0] 07/07/2016  
 HORIZONS 202342 baseline Q v2.0 OVARIAN [clean] 27/02/2017  
 HORIZONS 202342 baseline Q v1.0 NHL [tracked] 07/07/2016  
 HORIZONS 202342 baseline Q v2.0 NHL [clean] 27/02/2017  
 HORIZONS 202342 3 mo Q v1.0 BREAST [tracked] 21/09/2016  
 HORIZONS 202342 3 mo Q v2.0 BREAST [clean] 27/02/2017  
 HORIZONS 202342 3 mo Q v1.0 CERVICAL [tracked] 21/09/2016  
 HORIZONS 202342 3 mo Q v2.0 CERVICAL [clean] 27/02/2017  
 HORIZONS 202342 3 mo Q v1.0 ENDOMETRIAL [tracked] 21/09/2016  
 HORIZONS 202342 3 mo Q v2.0 ENDOMETRIAL [clean] 27/02/2017  
 HORIZONS 202342 3 mo Q v1.0 OVARIAN [tracked] 21/09/2016  
 HORIZONS 202342 3 mo Q v2.0 OVARIAN [clean] 21/09/2016  
 HORIZONS 202342 3 mo Q v2.0 NHL [clean] 27/02/2017  
 HORIZONS 202342 3 mo Q v1.0 NHL [tracked] 21/09/2016  
 HORIZONS 202342 9 mo Q v1.0 BREAST  
 HORIZONS 202342 9 mo Q v1.0 CERVICAL  
 HORIZONS 202342 9 mo Q v1.0 ENDOMETRIAL  
 HORIZONS 202342 9 mo Q v1.0 OVARIAN  
 HORIZONS 202342 9 mo Q v1.0 NHL  
 HORIZONS flyer for online completion of questionnaires v1.0 270217  
 HORIZONS - Online questionnaire email text V1.0 23.02.2017

**Is this a modified version of an amendment previously notified and not approved?**

☐ Yes ☒ No

**Summary of changes**

*Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study.*

*If this is a modified amendment, please explain how the modifications address the concerns raised previously by the ethics committee.*

*If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained.*

The baseline and 3 month questionnaire have been updated based on feedback from participants and some questionnaire measures have been added following stakeholder input. Clean and tracked changes of each

questionnaire are included with a contents page of the measures included.

The baseline gynaecological questionnaire is previously submitted as one questionnaire which covered the three gynae sub cohorts. These have now been separated out into cervical, endometrial and ovarian.

The 9 month timepoint questionnaire are submitted for review, along with a contents page of measures selected

A flyer explaining the online completion option for follow-up questionnaires has been produced to be sent with paper questionnaire.

The email text for the covering email to participants who have requested online questionnaire completion has been updated from the hard copy cover letter.

Four further sites have been selected to participate in HORIZONS;

Barts Health NHS Trust

St George's University Hospitals NHS Foundation Trust

NHS Lanarkshire

NHS Highlands

#### Any other relevant information

*Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is sought.*

#### List of enclosed documents

<i>Document</i>	<i>Version</i>	<i>Date</i>
HORIZONS 202342 Baseline Q v1.0 BREAST [tracked]	1.0	07/07/2016
HORIZONS 202342 Baseline Q v2.0 BREAST [clean]	2.0	27/02/2017
HORIZONS 202342 Baseline Q v1.0 CERVICAL [tracked from gynae v1.0]	1.0	07/07/2016
HORIZONS 202342 baseline Q v2.0 CERVICAL [clean]	2.0	27/02/2017
HORIZONS 202342 baseline Q v1.0 ENDOMETRIAL [tracked from gynae v1.0]	1.0	07/07/2016
HORIZONS 202342 baseline Q v2.0 ENDOMETRIAL [clean]	2.0	27/02/2017
HORIZONS 202342 baseline Q v1.0 OVARIAN [tracked from gynae v1.0]	1.0	07/07/2016
HORIZONS 202342 baseline Q v2.0 OVARIAN [clean]	2.0	27/02/2017
HORIZONS 202342 baseline Q v1.0 NHL [tracked]	1.0	07/07/2016
HORIZONS 202342 baseline Q v2.0 NHL [clean]	2.0	27/02/2017
HORIZONS 202342 3 mo Q v1.0 BREAST [tracked]	1.0	21/09/2016
HORIZONS 202342 3 mo Q v2.0 BREAST [clean]	2.0	27/02/2017
HORIZONS 202342 3 mo Q v1.0 CERVICAL [tracked]	1.0	21/09/2016
HORIZONS 202342 3 mo Q v2.0 CERVICAL [clean]	2.0	27/02/2017
HORIZONS 202342 3 mo Q v1.0 ENDOMETRIAL [tracked]	1.0	21/09/2016
HORIZONS 202342 3 mo Q v2.0 ENDOMETRIAL [clean]	2.0	27/02/2017
HORIZONS 202342 3 mo Q v1.0 OVARIAN [tracked]	1.0	21/09/2016
HORIZONS 202342 3 mo Q v2.0 OVARIAN [clean]	2.0	27/02/2017
HORIZONS 202342 3 mo Q v1.0 NHL [tracked]	1.0	21/09/2016
HORIZONS 202342 3 mo Q v2.0 NHL [clean]	2.0	27/02/2017
HORIZONS 202342 9 mo Q v1.0 BREAST	1.0	27/02/2017
HORIZONS 202342 9 mo Q v1.0 CERVICAL	1.0	27/02/2017

HORIZONS 202342 9 mo Q v1.0 ENDOMETRIAL	1.0	27/02/2017
HORIZONS 202342 9 mo Q v1.0 OVARIAN	1.0	27/02/2017
HORIZONS 202342 9 mo Q v1.0 NHL	1.0	27/02/2017
HORIZONS flyer for online completion of questionnaires	1.0	27/02/2017
HORIZONS - Online questionnaire email text	1.0	27/02/2017

#### Declaration by Chief Investigator

1. *I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.*
2. *I consider that it would be reasonable for the proposed amendment to be implemented.*

This section was signed electronically by Professor Claire Foster on 07/03/2017 15:14.

Job Title/Post: Director of Macmillan Survivorship Research Group  
 Organisation: Macmillan Survivorship Research Group  
 Email: clf1@soton.ac.uk

#### Declaration by the sponsor's representative

*I confirm the sponsor's support for this substantial amendment.*

This section was signed electronically by Mrs Sharon Davies-Dear on 10/03/2017 11:39.

Job Title/Post: Research Governance Officer  
 Organisation: University Hospital Southampton NHS Foundation Trust  
 Email: sharon.davies-dear@uhs.nhs.uk